Cargando…
Advances in Allogeneic Cancer Cell Therapy and Future Perspectives on “Off-the-Shelf” T Cell Therapy Using iPSC Technology and Gene Editing
The concept of allogeneic cell therapy was first presented over 60 years ago with hematopoietic stem cell transplantation. However, complications such as graft versus host disease (GVHD) and regimen-related toxicities remained as major obstacles. To maximize the effect of graft versus leukemia, whil...
Autores principales: | Furukawa, Yoshiki, Hamano, Yasuharu, Shirane, Shuichi, Kinoshita, Shintaro, Azusawa, Yoko, Ando, Jun, Nakauchi, Hiromitsu, Ando, Miki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773622/ https://www.ncbi.nlm.nih.gov/pubmed/35053386 http://dx.doi.org/10.3390/cells11020269 |
Ejemplares similares
-
Trigenic ADH5/ALDH2/ADGRV1 mutations in myelodysplasia with Usher syndrome
por: Kinoshita, Shintaro, et al.
Publicado: (2021) -
Persistent immune thrombocytopaenic purpura associated with SARS‐CoV‐2 infection
por: Furukawa, Yoshiki, et al.
Publicado: (2021) -
Sustainable Tumor-Suppressive Effect of iPSC-Derived Rejuvenated T Cells Targeting Cervical Cancers
por: Honda, Tadahiro, et al.
Publicado: (2020) -
Fail-Safe System against Potential Tumorigenicity after Transplantation of iPSC Derivatives
por: Itakura, Go, et al.
Publicado: (2017) -
Role of Cytokines and Growth Factors in the Manufacturing of iPSC-Derived Allogeneic Cell Therapy Products
por: Kao, Chen-Yuan, et al.
Publicado: (2023)